Tolerability of bacille Calmette-Guerin maintenance therapy for superficial bladder cancer

Urology

Volumn 57, Issue 5, 2001, Pages 883-888

  Saint, Fabien ^a   Irani, Jacques ^a   Patard, Jean Jacques ^a   Salomon, Laurent ^a   Hoznek, André ^a   Zammattio, Sylvie ^a   Debois, Henri ^b   Abbou, Claude C ^a   Chopin, Dominique K ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b SANOFI PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; TUBERCULIN;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; BLADDER CANCER; BLADDER INSTABILITY; CLINICAL TRIAL; COLLAPSE; CYSTITIS; CYTOPENIA; DRUG EFFICACY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEMATURIA; HEPATITIS; HUMAN; IMMUNOTHERAPY; KIDNEY ABSCESS; LIVER TOXICITY; LUNG TOXICITY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; MULTIVARIATE ANALYSIS; MYALGIA; PAIN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTATITIS; QUESTIONNAIRE; RASH; RECURRENCE RISK; RISK BENEFIT ANALYSIS; SEPSIS; SUPERFICIAL CANCER;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RECURRENCE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 0035035511     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(00)01117-1     Document Type: Article

References (21)

1. Intracavity bacillus Calmette-Guérin in the treatment of superficial bladder tumors
2. Experience with intravesical bacillus Calmette-Guérin therapy of superficial bladder tumors
3. Intravesical bacillus Calmette-Guérin prophylactic treatment for superficial bladder tumors; results of a controlled prospective study
4. The management of superficial bladder tumors and carcinoma in situ with intravesical bacillus Calmette-Guérin
5. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder; a randomized Southwest Oncology Group study
6. Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer
7. Does isoniazid reduce side effects of intravesical bacillus Calmette-Guérin therapy in superficial bladder cancer?; Interim results of European Organization for Research and Treatment of Cancer protocol 30911
8. Experience with bacillus Calmette-Guérin in patients with superficial bladder carcinoma
9. Systemic bacillus Calmette-Guérin infection, 'BCGitis', in patients treated by intravesical bacillus Calmette-Guérin therapy for bladder cancer
10. Durability of tumor free response for intravesical bacillus Calmette-Guérin therapy
11. Long term results of intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer
12. Clinicopathological evaluation of repeated courses of intravesical bacillus Calmette-Guérin instillation for preventing recurrence of initially resistant superficial bladder cancer
13. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer
14. Single course versus maintenance bacillus Calmette-Guérin therapy for superficial bladder tumors; a prospective randomized trial
15. The use of bacillus Calmette-Guérin in the therapy of bladder carcinoma in situ
16. A 12 versus 6-week course of bacillus Calmette-Guérin prophylaxis for the treatment of high risk superficial bladder cancer
17. Intravesical versus intravesical plus intradermal bacillus Calmette-Guérin; a prospective randomized study in patients with recurrent superficial bladder tumours
18. Prognostic factors in patients treated with intravesical bacillus Calmette-Guérin for superficial bladder cancer
19. The quality of life during intravesical bacillus Calmette-Guérin therapy
20. Genetically regulated response to intravesical bacillus Calmette-Guérin immunotherapy of orthotopic murine bladder tumour